Volume 22, Number 11—November 2016
Letter
Shigella flexneri with Ciprofloxacin Resistance and Reduced Azithromycin Susceptibility, Canada, 2015
Table
Antimicrobial susceptibility of the Shigella flexneri,serotype 2a pulsovar 21, isolated in Montreal, Quebec, Canada, 2015*
Antimicrobial agent | Disk diffusion, mm | MIC, mg/L | Interpretation |
---|---|---|---|
Ampicillin | 6 | ≥32 | R |
TMP/SMX | 6 | ≥320 | R |
Ciprofloxacin | 12 | ≥4 and 8 | R |
Nalidixic acid | 6 | NA | R |
Ceftriaxone | 33 | ≤0.25 | S |
Cefixime | 26 | 0.25 | S |
Azithromycin† | 6 | >256 | NS |
Tetracycline | 6 | 32 | R |
Chloramphenicol | NA | >256 | R |
Amoxicillin-clavulanic acid | 14 | 16 | I |
Ertapenem | NA | ≤0.5 | S |
Gentamicin |
21 |
≤1 |
S |
*I, intermediate; NA, not available; NS, nonsusceptible; R, resistant; S, susceptible; TMP/SMX, trimethoprim/sulfamethoxazole. †Azithromycin epidemiologic cutoff values for wild-type (MIC ≤8 mg/L) and non–wild-type (MIC ≥16 mg/L) Shigella flexneri (2) and the susceptibility and resistance breakpoints for the other 11 antimicrobial agents were CLSI Enterobacteriaceae breakpoints (2). |
Page created: October 19, 2016
Page updated: October 19, 2016
Page reviewed: October 19, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.